Welgene Biotech Co.,Ltd. (TPEX:6661)
Taiwan · Delayed Price · Currency is TWD 17.00
+0.20 (1.19%)
Aug 19, 2026, 11:54 AM CST
Welgene Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 398.92 | 375.94 | 322.55 | 280.55 | 321.9 | 312.65 | |
Revenue Growth | 15.25% | 16.55% | 14.97% | -12.85% | 2.96% | -21.46% |
Cost of Revenue | 232.05 | 219.76 | 186.71 | 160.83 | 180.1 | 179.38 |
Gross Profit | 166.87 | 156.18 | 135.84 | 119.72 | 141.8 | 133.27 |
Selling, General & Admin | 143.45 | 129.61 | 110.69 | 100.43 | 104.3 | 97.13 |
Research & Development | 26.28 | 26.51 | 25.85 | 24.15 | 21.63 | 21.64 |
Operating Expenses | 169.36 | 156.05 | 136.69 | 123.98 | 124.52 | 118.97 |
Operating Income | -2.49 | 0.13 | -0.85 | -4.26 | 17.29 | 14.3 |
Interest Expense | -4.7 | -3.41 | -2.97 | -2.62 | -0.28 | -0.43 |
Interest & Investment Income | 2.02 | 2.16 | 1.46 | 1.46 | 0.51 | 0.17 |
Earnings From Equity Investments | - | - | - | - | - | -2.89 |
Currency Exchange Gain (Loss) | -1.01 | -1.01 | 0.25 | 0.01 | -0.02 | - |
Other Non Operating Income (Expenses) | 4.5 | 3.28 | 3 | 1.69 | 0.25 | 0.18 |
EBT Excluding Unusual Items | -1.68 | 1.15 | 0.88 | -3.73 | 17.74 | 11.34 |
Gain (Loss) on Sale of Investments | - | - | - | - | -4.19 | 5.04 |
Gain (Loss) on Sale of Assets | 0.18 | 0.18 | 0.37 | -0.11 | - | 0.21 |
Other Unusual Items | - | - | - | 0.81 | - | - |
Pretax Income | -1.49 | 1.34 | 1.25 | -3.03 | 13.55 | 16.6 |
Income Tax Expense | -0.11 | 0.04 | 0.54 | 0.11 | 4.01 | 2.89 |
Earnings From Continuing Operations | -1.39 | 1.3 | 0.71 | -3.15 | 9.54 | 13.7 |
Minority Interest in Earnings | -0.26 | 0.03 | 0.4 | 0.5 | 0.01 | -0 |
Net Income | -1.64 | 1.33 | 1.11 | -2.65 | 9.55 | 13.7 |
Net Income to Common | -1.64 | 1.33 | 1.11 | -2.65 | 9.55 | 13.7 |
Net Income Growth | - | 20.14% | - | - | -30.29% | -53.98% |
Shares Outstanding (Basic) | 24 | 23 | 23 | 23 | 23 | 23 |
Shares Outstanding (Diluted) | 24 | 23 | 23 | 23 | 23 | 23 |
Shares Change | 1.49% | - | - | -0.10% | 0.93% | 10.99% |
EPS (Basic) | -0.07 | 0.06 | 0.05 | -0.11 | 0.41 | 0.59 |
EPS (Diluted) | -0.07 | 0.06 | 0.05 | -0.11 | 0.41 | 0.59 |
EPS Growth | - | 20.14% | - | - | -30.53% | -58.74% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -102.42 | -6.08 | 51.27 | -28.1 | 24.57 | 6.87 |
Free Cash Flow Per Share | -4.33 | -0.26 | 2.20 | -1.21 | 1.05 | 0.30 |
Dividend Per Share | - | - | - | - | 0.180 | 0.480 |
Dividend Growth | - | - | - | - | -62.50% | -56.44% |
Gross Margin | 41.83% | 41.54% | 42.11% | 42.67% | 44.05% | 42.63% |
Operating Margin | -0.62% | 0.03% | -0.27% | -1.52% | 5.37% | 4.57% |
Profit Margin | -0.41% | 0.35% | 0.34% | -0.94% | 2.97% | 4.38% |
Free Cash Flow Margin | -25.67% | -1.62% | 15.90% | -10.02% | 7.63% | 2.20% |
EBITDA | 15.19 | 14.54 | 14.54 | 9.48 | 24.44 | 22.23 |
EBITDA Margin | 3.81% | 3.87% | 4.51% | 3.38% | 7.59% | 7.11% |
D&A For EBITDA | 17.67 | 14.41 | 15.39 | 13.74 | 7.15 | 7.93 |
EBIT | -2.49 | 0.13 | -0.85 | -4.26 | 17.29 | 14.3 |
EBIT Margin | -0.62% | 0.03% | -0.27% | -1.52% | 5.37% | 4.57% |
Effective Tax Rate | - | 3.14% | 43.52% | - | 29.58% | 17.43% |